BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 4581992)

  • 41. [Diabetes therapy with a new antidiabetic Pro-Diaban].
    Dols W
    Ther Ggw; 1976 Mar; 115(3):428-36. PubMed ID: 772866
    [No Abstract]   [Full Text] [Related]  

  • 42. [Experimental and clinical pharmacology of oral antidiabetics].
    Cuomo V; Marino A
    Clin Ter; 1972 Sep; 62(6):505-52. PubMed ID: 4674507
    [No Abstract]   [Full Text] [Related]  

  • 43. Current status of oral agents in diabetes.
    Kilo C
    Compr Ther; 1982 Dec; 8(12):26-32. PubMed ID: 7160161
    [No Abstract]   [Full Text] [Related]  

  • 44. [Personal experience on the use of glybenclamide (a new oral hypoglycemic agent)].
    Rodríguez-Miñón JL; Arrieta F; Herrera JL
    Rev Clin Esp; 1970 May; 117(4):371-4. PubMed ID: 5471526
    [No Abstract]   [Full Text] [Related]  

  • 45. [Clinical experiences with prodiaban in diabetes mellitus].
    Gross W
    MMW Munch Med Wochenschr; 1974 Aug; 116(35):1509-12. PubMed ID: 4214136
    [No Abstract]   [Full Text] [Related]  

  • 46. [Clinical evaluation of Daonil--a new sulphonylurea derivative].
    Nowotna-Walcowa R; Rozyńska E
    Pol Tyg Lek; 1971 Jan; 26(2):65-7. PubMed ID: 5101252
    [No Abstract]   [Full Text] [Related]  

  • 47. [Glurenorm a new peroral antidiabetic agent belonging to the group of sulfonylurea compounds].
    Grujić M; Rizvanbegović B; Perinović M; Perinović ID
    Med Arh; 1976; 30(2):119-21. PubMed ID: 971371
    [No Abstract]   [Full Text] [Related]  

  • 48. [Risks of peroral treatment of diabetes].
    Rybka J
    Vnitr Lek; 1983 Nov; 29(11):1114-8. PubMed ID: 6659388
    [No Abstract]   [Full Text] [Related]  

  • 49. [Indications and limitations of oral hypoglycemic agents in the treatment of diabetes mellitus].
    Guillon J; Charbonnel B
    Cah Med; 1972 Nov; 13(14):999-1006. PubMed ID: 4646244
    [No Abstract]   [Full Text] [Related]  

  • 50. [Long term study of a new antidiabetic agent in 1183 cases].
    Riveline B
    Sem Hop Ther; 1974 Feb; 50(2):133-9. PubMed ID: 4612707
    [No Abstract]   [Full Text] [Related]  

  • 51. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results.
    Goldner MG; Knatterud GL; Prout TE
    JAMA; 1971 Nov; 218(9):1400-10. PubMed ID: 4941698
    [No Abstract]   [Full Text] [Related]  

  • 52. [Clinical evaluation of a new sulfonylurea (Ro-6-4563) in the treatment of stable diabetes in adults].
    Artega A; Soto S; Eyzaguirre J; Foradori A; Alliende ME
    Rev Med Chil; 1972 Jun; 100(6):635-8. PubMed ID: 5083349
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical use of glibenclamide in diabetes mellitus.
    Luntz GR
    Postgrad Med J; 1970 Dec; ():Suppl:84-7. PubMed ID: 5533303
    [No Abstract]   [Full Text] [Related]  

  • 54. [Experiences with Glibornurid, a new sulfonylurea derivative for the treatment of diabetes in adults].
    Rosenstiel K
    Med Welt; 1972 Sep; 23(36):1214-6. PubMed ID: 5079616
    [No Abstract]   [Full Text] [Related]  

  • 55. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
    Johnson JL; Wolf SL; Kabadi UM
    Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Progress in therapy for diabetes mellitus--insulin-secretion inducing oral hypoglycemic agents].
    Nagashima K; Inagaki N
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):737-41. PubMed ID: 19472523
    [No Abstract]   [Full Text] [Related]  

  • 57. [Three-year experience with the antidiabetic glibornurid (Glutril)].
    Hammerl H; Henk W; Köhn H; Kränzl C; Pichler O; Studlar M
    Wien Med Wochenschr; 1974 Jul; 124(27):448-52. PubMed ID: 4210108
    [No Abstract]   [Full Text] [Related]  

  • 58. Drugs for type 2 diabetes.
    Treat Guidel Med Lett; 2008 Jul; 6(71):47-54. PubMed ID: 18583949
    [No Abstract]   [Full Text] [Related]  

  • 59. [Clinical experience with the blood sugar reducing sulfonamide derivative glisoxepide].
    Petzoldt R; Riedesel G; Ramrath M; Grabs V; Haupt E; Schwedes U; Ewald W; Beyer J; Schöffling K
    Arzneimittelforschung; 1974 Mar; 24(0):429-32. PubMed ID: 4603399
    [No Abstract]   [Full Text] [Related]  

  • 60. [Oral antidiabetics].
    Bäbler M
    Schweiz Rundsch Med Prax; 1972 Feb; 61(8):242-6. PubMed ID: 4659095
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.